Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
New insights into signaling during myelination in zebrafish.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Alerting Network Dysfunction in Early Multiple Sclerosis.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
One calcitriol dose transiently increases Helios(+)FoxP3(+) T cells and ameliorates autoimmune demyelinating disease.
Alemtuzumab for the Treatment of Multiple Sclerosis
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Natalizumab Use During the Third Trimester of Pregnancy.
Spin-offs: Meet the structure specialists
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
Ustekinumab success in refractory Crohn’s disease
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis

Pages